{"id":26307,"date":"2024-06-27T09:59:57","date_gmt":"2024-06-27T07:59:57","guid":{"rendered":"https:\/\/www.icscyl.com\/mileon\/?p=26307"},"modified":"2024-06-24T10:06:03","modified_gmt":"2024-06-24T08:06:03","slug":"futurybles-semaglutida-oral-y-beneficio-cardio-nefroprotector","status":"publish","type":"post","link":"https:\/\/www.icscyl.com\/mileon\/otras-presentaciones\/2024-06-27\/futurybles-semaglutida-oral-y-beneficio-cardio-nefroprotector\/","title":{"rendered":"Futurybles: semaglutida oral y beneficio cardio\/nefroprotector"},"content":{"rendered":"<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"191\" height=\"148\" src=\"https:\/\/www.icscyl.com\/mileon\/wp-content\/uploads\/2024\/06\/Captura-de-pantalla-2024-06-24-a-las-10.03.56.png\" alt=\"\" class=\"wp-image-26309\"\/><\/figure>\n<\/div>\n\n\n<p>El 11 de Junio se present\u00f3 por el Dr. Muela esta sesi\u00f3n en la que se repas\u00f3 brevemente el contenido de las jornadas Futurybles, patrocinadas por Novo nordisk, centr\u00e1ndose en la utilidad de semaglutida para reducci\u00f3n de riesgo cardiovascular y su beneficio como f\u00e1rmaco nefroprotector, as\u00ed como resultados recientes en vida real. Al final se coment\u00f3 tambi\u00e9n la disponibilidad de Wegovy (semaglutida 2.4 subcut\u00e1nea), un f\u00e1rmaco disponible recientemente para el tratamiento de la obesidad. La presentaci\u00f3n se encuentra disponible en el enlace adjunto.<\/p>\n\n\n\n<div class=\"wp-block-file\"><a id=\"wp-block-file--media-4134dcbe-eaf4-4678-912f-453475e46712\" href=\"https:\/\/www.icscyl.com\/mileon\/wp-content\/uploads\/2024\/06\/Dr-Muela-futurybles.pdf\">Dr-Muela-futurybles<\/a><a href=\"https:\/\/www.icscyl.com\/mileon\/wp-content\/uploads\/2024\/06\/Dr-Muela-futurybles.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-4134dcbe-eaf4-4678-912f-453475e46712\">Descarga<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>El 11 de Junio se present\u00f3 por el Dr. Muela esta sesi\u00f3n en la que se repas\u00f3 brevemente el contenido de las jornadas Futurybles, patrocinadas por Novo nordisk, centr\u00e1ndose en la utilidad de semaglutida para reducci\u00f3n de riesgo cardiovascular y su beneficio como f\u00e1rmaco nefroprotector, as\u00ed como resultados recientes en vida real. Al final se [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[719],"tags":[946],"class_list":["post-26307","post","type-post","status-publish","format-standard","hentry","category-otras-presentaciones","tag-muela"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/26307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/comments?post=26307"}],"version-history":[{"count":1,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/26307\/revisions"}],"predecessor-version":[{"id":26310,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/posts\/26307\/revisions\/26310"}],"wp:attachment":[{"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/media?parent=26307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/categories?post=26307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.icscyl.com\/mileon\/wp-json\/wp\/v2\/tags?post=26307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}